Int J Biol Sci 2021; 17(6):1486-1496. doi:10.7150/ijbs.59149

Review

Development and application of therapeutic antibodies against COVID-19

Lin Ning1, Hamza B. Abagna2,3, Qianhu Jiang2,3, Siqi Liu2,3, Jian Huang2,3✉

1. School of Healthcare Technology, Chengdu Neusoft University, Sichuan, China
2. School of Life Science and Technology, University of Electronic Science and Technology of China, Sichuan, China
3. Center for Informational Biology, University of Electronic Science and Technology of China, Sichuan, China

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Ning L, Abagna HB, Jiang Q, Liu S, Huang J. Development and application of therapeutic antibodies against COVID-19. Int J Biol Sci 2021; 17(6):1486-1496. doi:10.7150/ijbs.59149. Available from https://www.ijbs.com/v17p1486.htm

File import instruction

Abstract

The pandemic of Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome 2 coronavirus (SARS-CoV-2) continues to be a global health crisis. Fundamental studies at genome, transcriptome, proteome, and interactome levels have revealed many viral and host targets for therapeutic interventions. Hundreds of antibodies for treating COVID-19 have been developed at preclinical and clinical stages in the format of polyclonal antibodies, monoclonal antibodies, and cocktail antibodies. Four products, i.e., convalescent plasma, bamlanivimab, REGN-Cov2, and the cocktail of bamlanivimab and etesevimab have been authorized by the U.S. Food and Drug Administration (FDA) for emergency use. Hundreds of relevant clinical trials are ongoing worldwide. Therapeutic antibody therapies have been a very active and crucial part of COVID-19 treatment. In this review, we focus on the progress of therapeutic COVID-19 antibody development and application, discuss corresponding problems and challenges, suggesting new strategies and solutions.

Keywords: therapeutic antibody, COVID-19, SARS-CoV-2, convalescent plasma, antibody cocktail, monoclonal antibody